PDCD1 and cancer: In clinical practice, antibodies to α-PD-1 (anti-PD-1), such as nivolumab, pembrolizumab, cemiplimab, sintilimab, camrelizumab, toripalimab, tislelizumab, zimberelimab, prolgolimab, and dostarlimab, have been successfully used in cancer treatment.